A5077686486- Amyloidosis: Diagnosis, Treatment, Outcomes
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Parathyroid Disorders and Treatments
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Lymphoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Pancreatitis Pathology and Treatment
- Drug Transport and Resistance Mechanisms
- Dermatological and Skeletal Disorders
- Immunodeficiency and Autoimmune Disorders
- Protein Kinase Regulation and GTPase Signaling
- Renal Diseases and Glomerulopathies
- Hematological disorders and diagnostics
- Pneumocystis jirovecii pneumonia detection and treatment
- IgG4-Related and Inflammatory Diseases
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Advanced Breast Cancer Therapies
- Alzheimer's disease research and treatments
- Peripheral Neuropathies and Disorders
Mayo Clinic in Arizona
2016-2025
Mayo Clinic
2016-2025
WinnMed
2016-2024
Mayo Clinic in Florida
2021-2024
University of Minnesota Rochester
2023
Janssen (Belgium)
2019
First Pavlov State Medical University of St. Petersburg
2019
McMaster University
2019
Rabin Medical Center
2009-2016
Tel Aviv University
2009-2016
The natural history, prognostication and optimal treatment of Richter transformation developed from chronic lymphocytic leukemia (CLL) are not well defined. We report the clinical characteristics outcomes a large series biopsy-confirmed (diffuse B-cell lymphoma or high grade lymphoma, n=204) cases diagnosed 1993 to 2018. After median follow up 67.0 months, overall survival (OS) was 12.0 months. Patients who received no prior for CLL had significantly better OS (median 46.3 vs. 7.8 months; P
PURPOSE Binary cardiac response assessment using biomarkers is prognostic in light chain amyloidosis. Previous studies suggested four-level responses N-terminal prohormone of brain natiuretic peptide improves prediction. This study was designed to validate graded criteria peptide/brain peptide. PATIENTS AND METHODS retrospective, multicenter included patients with amyloidosis who achieved at least a hematologic partial (PR) and were evaluable for response. Four tested on the basis...
Abstract Extramedullary multiple myeloma (EMM) can present either at initial diagnosis (de novo) or disease relapse (secondary) and confers an aggressive clinical course. Limited data exist for choosing the optimal therapy EMM this remains area of unmet need. After excluding paraskeletal primary plasma cell leukemia, we identified 204 (68%) patients with secondary 95 (32%) de novo between January 01, 2000 31 December, 2021. The median overall survival (OS) was 0.7 (95% CI: 0.6–0.9) years 3.6...
Patients with Waldenström macroglobulinemia (WM) have disparate outcomes. Newer therapies emerged since the development of International Prognostic Scoring System, and
Digoxin is considered contraindicated in light-chain (AL) amyloidosis, given reports of increased toxicity published 30-50 years ago. We sought to determine the frequency digoxin patients with AL.We identified 107 AL amyloidosis who received between 2000 and 2015.The median age was 65 dose estimated glomerular filtration rate were 0.125 mg/d 55 ml/min/1.73 m2, respectively. reduced 16% patients, mainly due high serum drug concentration or worsening renal function. The duration therapy 5...
Summary Improvement in survival Light chain (AL) amyloidosis has been seen over recent decades, enabling more patients to achieve long‐term survival. Patients with AL who survived ≥10 years from time of diagnosis ( n = 186) were the subject this study. Ten‐year survivors represented 22% total population. These characterized by favourable patient, organ and plasma cell features. Of note, trisomies less common among 10‐year compared those did not survive 10 years. All‐time best haematological...
Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical trials. We report outcomes of 36 patients treated at Mayo Clinic. Our cohort received median eight prior lines therapy. Six belantamab combination with other medications (pomalidomide, cyclophosphamide, thalidomide), 13 (36%) were 70 years or older, two had creatinine >2.5 mg/dL, one...
Clinical success with intravenous (IV) oncolytic virotherapy (OV) has to date been anecdotal. Here, we conducted a phase 1 clinical trial of systemic OV therapy and investigated the mechanisms action in responding T-cell lymphoma (TCL) patients. A single IV dose VSV-IFNβ-NIS was administered patients relapsed refractory hematologic malignancies determine safety efficacy across 4 levels (DL). Correlative studies were undertaken evaluate viremia, virus shedding, replication immune responses....
The use of an artificial intelligence electrocardiography (AI-ECG) algorithm has demonstrated its reliability in predicting the risk atrial fibrillation (AF) within general population. This study aimed to determine effectiveness AI-ECG score identifying patients with chronic lymphocytic leukemia (CLL) who are at high developing AF. We estimated probability AF based on among CLL extracted from Mayo Clinic database. Additionally, we computed and determined ability predict Among 754 newly...